Research profile
Tesamorelin
Tesamorelin stimulates growth hormone release. An approved U.S. prescription formulation is indicated for excess abdominal fat in adults with HIV-associated lipodystrophy.
- Randomized clinical trial
- Evaluation only
Amnavero
Tesamorelin
What the research found
In a randomized trial of 404 people with HIV and excess abdominal fat, visceral fat fell by 10.9% with tesamorelin and 0.6% with placebo over six months.
What remains uncertain
The trial focused on visceral fat in a specific population. The prescription label defines the indication and addresses risks such as elevated blood sugar.